Skip to main content

Table 2 Overall objective response rate of patients at cycle 3 and maintained to cycle 5 or end of treatment.

From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Timepoint ITT Population Evaluable Population
   Overall response to treatmenta (N = 74) (N = 40)
Cycle 3, Day 1   
   CR 0 0
   PR 3 (4.1)b 3 (7.5)
   SD 34 (45.9) 25 (62.5)
Cycle 5, Day 1   
   CR 0 0
   PR 3 (4.1) 3 (7.5)
   SD 16 (21.6) 13 (32.5)
End of treatment or early termination   
   CR 0 0
   PR 2 (2.7) 1 (2.5)
   SD 10 (13.5) 7 (17.5)
  1. ITT = intention-to-treat; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease
  2. a Response is based on the investigator's assessment using RECIST.
  3. b N (%).